Close menu




August 7th, 2025 | 07:30 CEST

Bayer and its billion-dollar problem! Evotec fails to impress analysts! AI stock NetraMark makes a splash!

  • Biotechnology
  • AI
  • Biotech
  • Pharma
Photo credits: pixabay.com

More positive news for AI insider tip NetraMark. The Company has secured a new customer for its AI platform designed to improve clinical trials. This could bring an end to the stock's sideways trend. Analysts continue to see significant upside. In contrast, analysts are cautious about Bayer's quarterly figures. The surprise stock of the year so far is facing a significant setback. The billion-dollar problems in the US are back on the table, weighing heavily on the stock. And what is Evotec doing? The sale of its site in France is intended to contribute to the Company's profitability. However, this only briefly boosted sentiment on the stock market. In the meantime, the stock has shifted into reverse. Rightly so?

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , EVOTEC SE INH O.N. | DE0005664809 , NETRAMARK HOLDINGS INC | CA64119M1059

Table of contents:


    NetraMark Holdings: Will a new customer trigger a breakout?

    Artificial intelligence (AI) is playing an increasingly important role in the development of new drugs. The advantages are clear: it saves time and money. NetraMark specializes in AI-assisted clinical trials through its proprietary platform NetraAI, and is steadily expanding its client base. Just two days ago, the Company announced a new partnership: Asklepion Pharmaceuticals will use NetraAI to analyze its key Phase III paediatric clinical trial. The study is investigating the efficacy of intravenous L-citrulline (CIT-003-01) in preventing acute lung injury in children who require cardiopulmonary bypass surgery due to congenital heart defects.

    NetraMark's AI analytics will help demonstrate the benefits of L-citrulline in specific patient subgroups and improve study results. Asklepion CEO Jeff Courtney commented: "We want to push the boundaries of drug development in paediatrics, and NetraMark's technology shows us a promising path forward."

    NetraMark is thus continuing its positive development and positive news flow. Most recently, NetraAI caused a sensation when it outperformed major competitors ChatGPT and DeepSeek in a comparative evaluation. In three independent studies focused on schizophrenia, depression, and pancreatic cancer, NetraAI was the only system able to reliably identify clinically relevant subgroups.

    Given these developments, it seems only a matter of time before the share, currently trading on Tradegate in Germany, breaks out of its sideways movement between EUR 0.80 and EUR 1.00 that has persisted since May. The price target set by analysts at Zacks Small-Cap Research is CAD 2.25.

    Evotec: Share price falls again

    Evotec shares continue to be a source of disappointment. The announced sale of peripheral businesses – or perhaps even crown jewels? – is now being implemented. Evotec recently announced a non-binding agreement with Sandoz regarding the possible sale of Just – Evotec Biologics EU, owner of the J.POD facility for the manufacture of biologics in Toulouse, France. Under the agreement, Sandoz would also acquire a technology license, thereby gaining access to Evotec's proprietary platform for the integrated development and advanced continuous manufacturing of biologics. The two companies have been working closely together at the Toulouse site since 2024.

    The agreement is part of Evotec's new strategy to drive sustainable and profitable growth. The further development of Just – Evotec Biologics would thus be less capital-intensive for the German biotech company in the future. Evotec would receive around USD 300 million for the site. Additional technology-related considerations, future development revenues, milestone payments, and product license fees are also planned.

    Evotec shares reacted positively to the news only briefly. They had been falling steadily over the previous six trading days. The share price is now back well below EUR 7.

    Bayer: Billion-dollar lawsuits are back

    Bayer shares have been one of the positive surprises on the DAX so far this year. The news flow from the pharmaceutical sector was positive, and the lawsuits in the US were ignored. Yesterday, this scenario took a hit, and investors sent the share price down by over 5%.

    The reason was the second quarter report. Although the currency-adjusted annual forecast was raised just a few days ago, investors were not at all pleased with some of the details in the quarterly report. Special items resulted in a consolidated loss of around EUR 200 million. This is attributable to the ongoing proceedings in the US relating to glyphosate. The Leverkusen-based company had to set aside further provisions for this. Free cash flow also declined significantly, falling from EUR 1.27 billion to EUR 125 million.

    The fact that adjusted profit rose significantly and net financial debt was reduced by 9.5% to EUR 33.3 billion did not deter investors from selling the stock. Analysts were also less than enthusiastic. By midday, Jefferies, JPMorgan, and UBS had confirmed their "Hold" recommendations.


    Bayer has once again shown that the lawsuit issue could resurface at any time. This makes the Company difficult to assess. The news flow for NetraMark remains positive. This should soon catapult the share price out of its sideways movement. Evotec's new focus on profitability at the expense of growth continues to be unpopular with investors and analysts.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read

    Commented by Jens Castner on November 18th, 2026 | 05:40 CET

    Treasures from the depths, a slump in the stock market: Lynas, Almonty and Cameco tempt with low share prices

    • Critical raw materials
    • Rare earths
    • Tungsten
    • Uranium
    • Almonty Industries
    • Cameco
    • AI
    • Lynas Rare Earths

    Without rare earths, no electric motors; without tungsten, no defence industry; without uranium, no nuclear power. The West needs these raw materials more urgently than ever and depends on a handful of suppliers that mine in politically stable countries. Yet shares in Lynas Rare Earths, Almonty Industries and Cameco are falling as if there were no shortage – down by one-third to two-thirds from their highs for the year. We have taken a close look at the three producers following their latest quarterly results. One of the shares has reached bargain levels.

    Read